Figure S11 from Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer

Figure S11. Mean usage of myeloid cNMF programs per myeloid cell subset at (A) baseline, (B) post-chemotherapy (FU1) and (C) post-immunotherapy (FU2). Mean usage of T cell cNMF programs per T cell cell subset at (D) baseline, (E) postchemotherapy (FU1) and (F) post-immunotherapy (FU2).